

FY 2023 presentation March 6, 2024



### **Forward-looking Statement**

This company presentation includes forward-looking statements which are not historical facts but statements regarding future expectations instead. These forward-looking statements include without limitation, those regarding Herantis' future financial position and results of operations, the company's strategy, objectives, future developments in the markets in which the company participates or is seeking to participate or anticipated regulatory changes in the markets in which the company operates or intends to operate. In some cases, forward-looking statements can be identified by terminology such as "aim," "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "guidance," "intend," "may," "plan," "potential," "predict," "projected," "should" or "will" or the negative of such terms or other comparable terminology. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future.

Forward-looking statements are not guarantees of future performance and are based on numerous assumptions. The company's actual results of operations, including the company's financial condition and liquidity and the development of the industry in which the company operates, may differ materially from (and be more negative than) those made in, or suggested by, the forward-looking statements contained in this company release. Factors, including risks and uncertainties that could cause these differences include, but are not limited to risks associated with implementation of Herantis' strategy, risks and uncertainties associated with the development and/or approval of Herantis' drug candidates, ongoing and future clinical trials and expected trial results, the ability to commercialize drug candidates, technology changes and new products in Herantis' potential market and industry, Herantis' freedom to operate in respect of the products it develops (which freedom may be limited, e.g., by competitors' patents), the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. In addition, even if Herantis' historical results of operations, including the company's financial condition and liquidity and the development of the industry in which the company operates, are consistent with the forward-looking statements contained in this company release, those results or developments may not be indicative of results or developments in subsequent periods.





### **Herantis in Brief**



Herantis Pharma plc was founded in Helsinki, Finland in 2008; Listed at Nasdaq First North Helsinki



**Developing disease-modifying treatment** to address the unmet clinical need in Parkinson's disease and other neurodegenerative diseases



Lead asset **HER-096** is a small engineered peptide molecule with a **unique mechanism of action** and **subcutaneous injection** as an **easy route of administration** 



**Phase 1a clinical trial readout** in October 2023: Good safety profile, blood-brain barrier (BBB) penetration demonstrated

# \*\*\*

Ambition: engage with a partner before Phase 2

### Normal function of the dopaminergic neurons



4

### Parkinson's disease: dopaminergic neurons degenerate in mid-brain (sustantia nigra)



PHARMA

DISORDER

### Preclinical data: HER-096 acts on the key mechanisms of Parkinson's disease



### HER-096 restores the normal function of the dopaminergic neurons





### **Status of HER-096 Program**

- Manufacturing
  - > HER-096 bulk manufactured by solid phase peptide synthesis, current scale 1000 grams, straightforward further scale-up
  - Phase 1b GMP manufacturing ongoing
  - > Formulation development work on-going to decrease the volume of injection
- Preclinical toxicology studies
  - > 28-day daily dosing GLP toxicology study completed
  - > 6-month toxicology study planned to start in late 2024
- Clinical
  - ➢ Phase 1a completed in 2023 → data support moving forward with subcutaneous HER-096 dosing
  - Phase 1b planned to be started in 2H 2024
- IPR

Composition of matter patent filed in Dec 2019 (WO2021123050A1)



• HER-096 Phase 1a clinical trial met all primary and secondary endpoints

In October, the read-out from the clinical trial demonstrated favorable safety and tolerability profile, fast uptake of HER-096, and significant HER-096 concentration in the cerebrospinal fluid (CSF) after a single subcutaneous injection.

Funding/financing

- >€2.5 million grant funding from the EIC Accelerator program over the next two years secured in April.
- $\succ$  Direct equity investment term sheet from EIC Fund of up to €15 million signed in July.
- Successfully completion of a directed share issue raising gross €4.5 million in December.
- Strengthening of the equity
  - ➢ Business Finland reached the positive decision in September of waiving off €4.5 million of the of the loans granted by it to Herantis for the development of CDNF



### **Events after the reporting period**

- March 4th, Herantis announced two poster presentations at the AD/PD 2024 conference.
  - Phase 1a first-in-human trial results of HER-096 to be presented to the scientific audience for the first time.
  - Preclinical data shows that HER-096 promotes functional recovery and regeneration of stressed neurons.



### Net profit for the year of 2023 due to cost savings and extraordinary items



#### **OPEX by item** (EUR thousands)



- Business Finland waived off MEUR 4.5 of the CDNF loans.
- European Innovation Council (EIC) grant program of MEUR 0.8.

PHARMA

- 37% cost reduction vs 2022
- Headcount reduction
- Focus on developing HER-096
- Cost savings measures

#### **Profit/Loss** (EUR thousands)



Results improvement due to:

- Waiving off loans by Business Finland
- Completed bankruptcy proceedings of subsidiary (cash in)
- Cost savings measures
- Headcount reduction
- EIC grant

### Herantis's equity position strengthening during 2023

Cash position (EUR thousands)



Cash flow from operating activities (EUR thousands)



Equity (EUR thousands)



- Herantis raised EUR 4.5 million in a directed share issue in December 2023.
- In addition to cash at banks (EUR 5.5 million): EUR 985 thousands is invested in short-term fixed income securities.

• The significant improvement in cash flow from operating activities relates mainly to cost cutting measurement.

• Strengthening of equity due to:

- Waiving of Business Finland CDNF loan of EUR 4.5 million
- Directed share issue of EUR 4.5 million





### 2024 milestones for HER-096

Phase 1b clinical trial application submitted (targeted 1H/2024)

Phase 1b clinical trial application approved (targeted 2H/2024)

First Parkinson's patient dosed with HER-096 in a Phase 1b trial (targeted 2H/2024)

### Seeking a partner for HER-096 to co-develop future potential





### Herantis as an investment



HERANTIS

### Summary



# What we want to achieve with HER-096?



## Evidence of subcutaneous HER-096

Next steps

Strategy

To develop a treatment to slow or stop the progression of Parkinson's disease with symptomatic relief

- Therapeutic concentration of HER-096 in the central nervous system in humans
- Good safety and tolerability profile in humans
- Therapeutic effects in aged mouse model of Parkinson's disease
- Phase 1b to start in 2024 (safety, tolerability of multiple subcutaneous dosing in PD patients)
- Prepare for Phase 2 readiness
- Explore HER-096 in other indications

Find a development partner for HER-096



## Thank you!

Contact details: CEO Antti Vuolanto, antti.vuolanto@herantis.com CFO Tone Kvåle, tone.kvale@herantis.com

